Tg Therapeutics (TGTX) Accounts Payables (2013 - 2026)
Tg Therapeutics (TGTX) posted quarterly Accounts Payables of $148.8 million for Q1 2026, up 429.7% year-over-year from $28.1 million in Q1 2025, and up 38.45% quarter-over-quarter from $107.5 million in Q4 2025.
Tg Therapeutics (TGTX) Accounts Payables (2013 - 2026) Analysis & Trends
Tg Therapeutics' Accounts Payables history runs 14 years deep, the most recent figure standing at $148.8 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 429.7% year-over-year to $148.8 million; the TTM figure through Mar 2026 stood at $148.8 million (up 429.7% YoY), while the FY2025 annual figure was $107.5 million, up 84.42% from the prior year.
- Accounts Payables for Q1 2026 stood at $148.8 million, up from $107.5 million in the prior quarter.
- The five-year high for Accounts Payables was $148.8 million in Q1 2026, with the low at $28.1 million in Q1 2025.
- The 5-year median for Accounts Payables is $58.3 million (2024), against an average of $72.2 million.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables slumped 67.8% in 2025, then surged 429.7% in 2026.
- Tg Therapeutics' Accounts Payables stood at $42.0 million in 2022, then retreated by 8.44% to $38.5 million in 2023, then jumped by 51.53% to $58.3 million in 2024, then jumped by 84.42% to $107.5 million in 2025, then soared by 38.45% to $148.8 million in 2026.
- Business Quant data shows TGTX's Accounts Payables at $148.8 million in Q1 2026, $107.5 million in Q4 2025, and $112.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 213.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.69 Mn |
| Mar 31, 2026 | 148.85 Mn |
| Dec 31, 2025 | 107.51 Mn |
| Sep 30, 2025 | 112.34 Mn |
| Jun 30, 2025 | 134.02 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Dec 31, 2024 | 58.30 Mn |
| Sep 30, 2024 | 101.41 Mn |
| Jun 30, 2024 | 93.47 Mn |
| Mar 31, 2024 | 87.27 Mn |
| Dec 31, 2023 | 38.47 Mn |
| Sep 30, 2023 | 39.74 Mn |
| Jun 30, 2023 | 62.95 Mn |
| Mar 31, 2023 | 57.09 Mn |
| Dec 31, 2022 | 42.02 Mn |
| Sep 30, 2022 | 29.73 Mn |
| Jun 30, 2022 | 37.22 Mn |
| Mar 31, 2022 | 49.67 Mn |
| Dec 31, 2021 | 51.29 Mn |
| Sep 30, 2021 | 44.70 Mn |